世界の経皮的血管形成術(PTA)経皮的薬剤溶出性バルーン(DEB)市場:医療機器パイプライン分析2016

◆英語タイトル:Peripheral Transluminal Angioplasty Peripheral Drug Eluting Balloons (DEB) - Medical Devices Pipeline Assessment, 2016
◆商品コード:GDME0216EPD
◆発行会社(調査会社):GlobalData
◆発行日:2016年8月1日
◆ページ数:87
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:医療機器
◆販売価格オプション(消費税別)
Single UserUSD2,500 ⇒換算¥285,000見積依頼/購入/質問フォーム
Site License(同一国内共有可)USD5,000 ⇒換算¥570,000見積依頼/購入/質問フォーム
Enterprisewide License(複数国内共有可)USD7,500 ⇒換算¥855,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(支払期限と方法は調整可能、振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※レポート購入後、該当レポートに記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。GlobalData社の概要及び新刊レポートはこちらでご確認いただけます。



当調査レポートでは、経皮的血管形成術(PTA)経皮的薬剤溶出性バルーン(DEB)のグローバル製品パイプライン動向について調査・分析し、以下の構成でお届けいたします。
・経皮的血管形成術(PTA)経皮的薬剤溶出性バルーン(DEB)の概要
・経皮的血管形成術(PTA)経皮的薬剤溶出性バルーン(DEB)の開発動向:開発段階別分析
・経皮的血管形成術(PTA)経皮的薬剤溶出性バルーン(DEB)の開発動向:セグメント別分析
・経皮的血管形成術(PTA)経皮的薬剤溶出性バルーン(DEB)の開発動向:領域別分析
・経皮的血管形成術(PTA)経皮的薬剤溶出性バルーン(DEB)の開発動向:規制Path別分析
・経皮的血管形成術(PTA)経皮的薬剤溶出性バルーン(DEB)の開発動向:承認日(推定)別分析
・企業別経皮的血管形成術(PTA)経皮的薬剤溶出性バルーン(DEB)の開発動向(パイプライン製品、進行中の治験)
・経皮的血管形成術(PTA)経皮的薬剤溶出性バルーン(DEB)の最近動向
【レポートの概要】

Peripheral Transluminal Angioplasty Peripheral Drug Eluting Balloons (DEB) – Medical Devices Pipeline Assessment, 2016

Summary

GlobalData’s Medical Devices sector report, “Peripheral Transluminal Angioplasty Peripheral Drug Eluting Balloons (DEB) – Medical Devices Pipeline Assessment, 2016″ provides an overview of Peripheral Transluminal Angioplasty Peripheral Drug Eluting Balloons (DEB) currently in pipeline stage.

The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Peripheral Transluminal Angioplasty Peripheral Drug Eluting Balloons (DEB) pipeline products.

This report is prepared using data sourced from in-house databases, secondary and primary research by GlobalData’s team of industry experts.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope

- Extensive coverage of the Peripheral Transluminal Angioplasty Peripheral Drug Eluting Balloons (DEB) under development
- The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
- The report reviews the major players involved in the development of Peripheral Transluminal Angioplasty Peripheral Drug Eluting Balloons (DEB) and list all their pipeline projects
- The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
- The report provides key clinical trial data of ongoing trials specific to pipeline products
- Recent developments in the segment / industry

Reasons to buy

The report enables you to –
- Formulate significant competitor information, analysis, and insights to improve R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of Peripheral Transluminal Angioplasty Peripheral Drug Eluting Balloons (DEB) under development
- Develop market-entry and market expansion strategies
- Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
- In-depth analysis of the product’s current stage of development, territory and estimated launch date

【レポートの目次】

1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 5
1.2 List of Figures 7
2 Introduction 8
2.1 Peripheral Transluminal Angioplasty Peripheral Drug Eluting Balloons (DEB) Overview 8
3 Products under Development 9
3.1 Peripheral Transluminal Angioplasty Peripheral Drug Eluting Balloons (DEB) – Pipeline Products by Stage of Development 9
3.2 Peripheral Transluminal Angioplasty Peripheral Drug Eluting Balloons (DEB) – Pipeline Products by Territory 10
3.3 Peripheral Transluminal Angioplasty Peripheral Drug Eluting Balloons (DEB) – Pipeline Products by Regulatory Path 11
3.4 Peripheral Transluminal Angioplasty Peripheral Drug Eluting Balloons (DEB) – Pipeline Products by Estimated Approval Date 12
3.5 Peripheral Transluminal Angioplasty Peripheral Drug Eluting Balloons (DEB) – Ongoing Clinical Trials 13
4 Peripheral Transluminal Angioplasty Peripheral Drug Eluting Balloons (DEB) – Pipeline Products under Development by Companies 14
4.1 Peripheral Transluminal Angioplasty Peripheral Drug Eluting Balloons (DEB) Companies – Pipeline Products by Stage of Development 14
4.2 Peripheral Transluminal Angioplasty Peripheral Drug Eluting Balloons (DEB) – Pipeline Products by Stage of Development 15
5 Peripheral Transluminal Angioplasty Peripheral Drug Eluting Balloons (DEB) Companies and Product Overview 16
5.1 AnGes MG, Inc. Company Overview 16
5.1.1 AnGes MG, Inc. Pipeline Products & Ongoing Clinical Trials Overview 16
5.2 AngioCure, Inc. Company Overview 18
5.2.1 AngioCure, Inc. Pipeline Products & Ongoing Clinical Trials Overview 18
5.3 AVIDAL Vascular GmbH Company Overview 19
5.3.1 AVIDAL Vascular GmbH Pipeline Products & Ongoing Clinical Trials Overview 19
5.4 Bayer HealthCare AG Company Overview 20
5.4.1 Bayer HealthCare AG Pipeline Products & Ongoing Clinical Trials Overview 20
5.5 Contego Medical, LLC Company Overview 22
5.5.1 Contego Medical, LLC Pipeline Products & Ongoing Clinical Trials Overview 22
5.6 Elixir Medical Corporation Company Overview 23
5.6.1 Elixir Medical Corporation Pipeline Products & Ongoing Clinical Trials Overview 23
5.7 eucatech AG Company Overview 24
5.7.1 eucatech AG Pipeline Products & Ongoing Clinical Trials Overview 24
5.8 Lifetech Scientific (Shenzhen) Co., Ltd. Company Overview 25
5.8.1 Lifetech Scientific (Shenzhen) Co., Ltd. Pipeline Products & Ongoing Clinical Trials Overview 25
5.9 Medtronic plc Company Overview 26
5.9.1 Medtronic plc Pipeline Products & Ongoing Clinical Trials Overview 26
5.10 Micell Technologies, Inc. Company Overview 28
5.10.1 Micell Technologies, Inc. Pipeline Products & Ongoing Clinical Trials Overview 28
5.11 Nipro Corporation Company Overview 30
5.11.1 Nipro Corporation Pipeline Products & Ongoing Clinical Trials Overview 30
5.12 NuVascular Technologies Inc Company Overview 31
5.12.1 NuVascular Technologies Inc Pipeline Products & Ongoing Clinical Trials Overview 31
5.13 QT Vascular Ltd. Company Overview 32
5.13.1 QT Vascular Ltd. Pipeline Products & Ongoing Clinical Trials Overview 32
5.14 QualiMed Innovative Medizinprodukte GmbH Company Overview 36
5.14.1 QualiMed Innovative Medizinprodukte GmbH Pipeline Products & Ongoing Clinical Trials Overview 36
5.15 Rontis AG Company Overview 37
5.15.1 Rontis AG Pipeline Products & Ongoing Clinical Trials Overview 37
5.16 SiL Vascular Ltd Company Overview 38
5.16.1 SiL Vascular Ltd Pipeline Products & Ongoing Clinical Trials Overview 38
5.17 SurModics, Inc. Company Overview 39
5.17.1 SurModics, Inc. Pipeline Products & Ongoing Clinical Trials Overview 39
5.18 Terumo Corporation Company Overview 44
5.18.1 Terumo Corporation Pipeline Products & Ongoing Clinical Trials Overview 44
5.19 The Spectranetics Corporation Company Overview 46
5.19.1 The Spectranetics Corporation Pipeline Products & Ongoing Clinical Trials Overview 46
5.20 Vascular Nanotransfer Technologies Company Overview 52
5.20.1 Vascular Nanotransfer Technologies Pipeline Products & Ongoing Clinical Trials Overview 52
6 Peripheral Transluminal Angioplasty Peripheral Drug Eluting Balloons (DEB) – Recent Developments 54
6.1 Jul 21, 2016: Federal Circuit Court Rules in Appeal 54
6.2 Jul 20, 2016: 12-month Results of the ILLUMENATE European Randomized Clinical Trial to be Presented at the Amputation Prevention Symposium 54
6.3 Jul 15, 2016: Daiichi Sankyo to Raise USD713.4 Million in Public Offering of 0.81% 5th Series Bonds Due 2036 54
6.4 Jul 15, 2016: Daiichi Sankyo to Raise USD237.8 Million in Public Offering of 1.2% 6th Series Bonds Due 2046 55
6.5 Jul 13, 2016: Medtronic Receives FDA Approval for IN.PACT Admiral DCB 150 mm Lengths 55
6.6 Jul 13, 2016: Boston Scientific Elects Yoshiaki Fujimori to Board of Directors 56
6.7 Jun 30, 2016: FTSE Russell Selects Daiichi Sankyo for FTSE4Good Global Index 56
6.8 Jun 30, 2016: NuVasive Agrees to Settle Patent Litigation With Medtronic 56
6.9 Jun 08, 2016: Boston Scientific Announces Restructuring Program to Support Long-Term Growth and Innovation 57
6.10 Jun 06, 2016: Medtronic Outlines Future Growth Vision at Investor Day 57
6.11 Jun 01, 2016: Second Interim Analysis on ILLUMENATE Global Study Presented on Spectranetics’ Stellarex drug-coated balloon at NCVH 58
6.12 May 31, 2016: Medtronic Reports Fourth Quarter and Fiscal Year 2016 Financial Results 59
6.13 May 16, 2016: iVascular Receives CE Mark Approval for LUMINOR 18 Drug Eluting Balloon 61
6.14 May 12, 2016: Daiichi Sankyo Announces Changes to Representative Director and Members of the Board 62
6.15 May 06, 2016: The outcome of arbitration proceeding with certain former shareholders of Ranbaxy 62
6.16 Apr 26, 2016: 12-Month Interim ILLUMENATE Global Study Data Presented on Spectranetics’ Stellarex drug-coated balloon at Charing Cross 63
6.17 Apr 26, 2016: Medtronic IN.PACT Admiral DCB Maintains Durable, Consistent and Safe Outcomes in Challenging Peripheral Cases 64
6.18 Apr 25, 2016: QT Vascular Submits IDE Requesting Permission to Begin Pivotal Trial of Its Drug-Coated Chocolate Balloon in The United States 66
6.19 Apr 06, 2016: SurModics Announces First Patient Enrolled in IDE Study of SurVeil Drug-Coated Balloon 67
6.20 Feb 10, 2016: QT Vascular Announces Another Positive Outcome in Litigation with Spectranetics/Angioscore 68
6.21 Jan 26, 2016: BIOTRONIK Announces Expansion Of Passeo-18 Lux Drug-Coated Balloon Portfolio 68
6.22 Jan 11, 2016: Medtronic IN.PACT Admiral DEB Receives CE Mark For Treatment Of AV Access In Patients With End-Stage Renal Disease 69
6.23 Dec 14, 2015: Medtronic Announces New High-Tech Facility in Galway; Building on Global Synergies 70
6.24 Nov 26, 2015: Update On AngioScore Litigation – QT Vascular Ltd 71
6.25 Nov 20, 2015: BIOTRONIK Announces Improved Patient Outcomes with Innovative “Combination Therapy” for Peripheral Artery Disease 71
6.26 Nov 02, 2015: IN.PACT Admiral Drug-Coated Balloon Cost-Effectiveness Study and Global Study Results of In-Stent Restenosis Population Highlighted in Late Breaking Clinical Trials at VIVA 2015 72
6.27 Nov 02, 2015: Medtronic Begins REALITY Study To Assess IN.PACT Admiral DCB In Patients With PAD 74
6.28 Oct 14, 2015: Medtronic Drug-Coated Balloon Sustains Superiority Over Balloon Angioplasty at Two Years in Patients with Peripheral Arterial Disease 75
6.29 Oct 05, 2015: SurModics Receives FDA IDE Approval for Early Feasibility Study of the SurVeil Drug-Coated Balloon 76
6.30 Oct 05, 2015: QT Vascular Announces Interim Clinical Trial Results Of Chocolate Touch 78
6.31 Oct 05, 2015: SurModics Receives FDA IDE Approval for Early Feasibility Study of the SurVeil Drug-Coated Balloon 79
6.32 Sep 15, 2015: New Technique at Morris Hospital Improves Treatment of Peripheral Artery Disease 80
6.33 Sep 07, 2015: QT Vascular Announces CE Mark Clearance Of Chocolate Touch By LRQA 0088 80
6.34 Aug 03, 2015: CMS Grants New Technology Add-On Payment for Inpatient Use of Medtronic’s Drug-Coated Balloon 81
6.35 Jul 29, 2015: Spectranetics Completes Enrollment in ILLUMENATE Pivotal Study to Assess Safety and Efficacy of Stellarex Drug-Coated Balloon Technology 82
7 Appendix 84
7.1 Methodology 84
7.2 About GlobalData 86
7.3 Contact Us 86
7.4 Disclaimer 87

1.1 List of Tables
Table 1: Peripheral Transluminal Angioplasty Peripheral Drug Eluting Balloons (DEB) - Pipeline Products by Stage of Development 9
Table 2: Peripheral Transluminal Angioplasty Peripheral Drug Eluting Balloons (DEB) - Pipeline Products by Territory 10
Table 3: Peripheral Transluminal Angioplasty Peripheral Drug Eluting Balloons (DEB) - Pipeline Products by Regulatory Path 11
Table 4: Peripheral Transluminal Angioplasty Peripheral Drug Eluting Balloons (DEB) - Pipeline Products by Estimated Approval Date 12
Table 5: Peripheral Transluminal Angioplasty Peripheral Drug Eluting Balloons (DEB) - Ongoing Clinical Trials 13
Table 6: Peripheral Transluminal Angioplasty Peripheral Drug Eluting Balloons (DEB) Companies - Pipeline Products by Stage of Development 14
Table 7: Peripheral Transluminal Angioplasty Peripheral Drug Eluting Balloons (DEB) - Pipeline Products by Stage of Development 15
Table 8: AnGes MG, Inc. Pipeline Products & Ongoing Clinical Trials Overview 16
Table 9: Collategene Drug-Eluting Balloon Catheter - Product Status 16
Table 10: Collategene Drug-Eluting Balloon Catheter - Product Description 17
Table 11: NF-kB Decoy Oligo Coated PTA Balloon Catheter - Product Status 17
Table 12: NF-kB Decoy Oligo Coated PTA Balloon Catheter - Product Description 17
Table 13: AngioCure, Inc. Pipeline Products & Ongoing Clinical Trials Overview 18
Table 14: AngioCure TOP-C Smart Balloon Catheter - Product Status 18
Table 15: AngioCure TOP-C Smart Balloon Catheter - Product Description 18
Table 16: AVIDAL Vascular GmbH Pipeline Products & Ongoing Clinical Trials Overview 19
Table 17: WOMBAT - Peripheral Version - Product Status 19
Table 18: WOMBAT - Peripheral Version - Product Description 19
Table 19: Bayer HealthCare AG Pipeline Products & Ongoing Clinical Trials Overview 20
Table 20: Cotavance Paclitaxel Coated Balloon Angioplasty Catheter - Product Status 20
Table 21: Cotavance Paclitaxel Coated Balloon Angioplasty Catheter - Product Description 21
Table 22: Contego Medical, LLC Pipeline Products & Ongoing Clinical Trials Overview 22
Table 23: Tibial Artery Drug Eluting Balloon - Product Status 22
Table 24: Tibial Artery Drug Eluting Balloon - Product Description 22
Table 25: Elixir Medical Corporation Pipeline Products & Ongoing Clinical Trials Overview 23
Table 26: Peripheral Vascular Resorbable Scaffold - Product Status 23
Table 27: Peripheral Vascular Resorbable Scaffold - Product Description 23
Table 28: eucatech AG Pipeline Products & Ongoing Clinical Trials Overview 24
Table 29: Support - Product Status 24
Table 30: Support - Product Description 24
Table 31: Lifetech Scientific (Shenzhen) Co., Ltd. Pipeline Products & Ongoing Clinical Trials Overview 25
Table 32: PTA Drug Eluting Balloon - Product Status 25
Table 33: PTA Drug Eluting Balloon - Product Description 25
Table 34: Medtronic plc Pipeline Products & Ongoing Clinical Trials Overview 26
Table 35: DCB BTK - Product Status 26
Table 36: DCB BTK - Product Description 27
Table 37: Micell Technologies, Inc. Pipeline Products & Ongoing Clinical Trials Overview 28
Table 38: Drug-Coated Balloon - Product Status 28
Table 39: Drug-Coated Balloon - Product Description 29
Table 40: Nipro Corporation Pipeline Products & Ongoing Clinical Trials Overview 30
Table 41: Peripheral Drug-Eluting Balloon - Product Status 30
Table 42: Peripheral Drug-Eluting Balloon - Product Description 30
Table 43: NuVascular Technologies Inc Pipeline Products & Ongoing Clinical Trials Overview 31
Table 44: NuSpun DE Balloon - Product Status 31
Table 45: NuSpun DE Balloon - Product Description 31
Table 46: QT Vascular Ltd. Pipeline Products & Ongoing Clinical Trials Overview 32
Table 47: Chocolate Touch PTA Drug Coated Balloon - Product Status 32
Table 48: Chocolate Touch PTA Drug Coated Balloon - Product Description 33
Table 49: Silk PTA Balloon Catheter - Product Status 33
Table 50: Silk PTA Balloon Catheter - Product Description 33
Table 51: QT Vascular Ltd. - Ongoing Clinical Trials Overview 34
Table 52: Chocolate Touch PTA Drug Coated Balloon - First in Human Evaluation of the Drug-coated Chocolate Balloon for Percutaneous Transluminal Revascularization of Infrainguinal Arterial Disease 35
Table 53: Chocolate Touch PTA Drug Coated Balloon - Pivotal Trial of Drug-coated Chocolate Balloon in The United States 35
Table 54: QualiMed Innovative Medizinprodukte GmbH Pipeline Products & Ongoing Clinical Trials Overview 36
Table 55: Kinesyx-Based Peripheral Drug Coated Balloon - Product Status 36
Table 56: Kinesyx-Based Peripheral Drug Coated Balloon - Product Description 36
Table 57: Rontis AG Pipeline Products & Ongoing Clinical Trials Overview 37
Table 58: Drug Eluting Dilatation Catheter - Product Status 37
Table 59: Drug Eluting Dilatation Catheter - Product Description 37
Table 60: SiL Vascular Ltd Pipeline Products & Ongoing Clinical Trials Overview 38
Table 61: Peripheral Vascular Balloon - Product Status 38
Table 62: Peripheral Vascular Balloon - Product Description 38
Table 63: SurModics, Inc. Pipeline Products & Ongoing Clinical Trials Overview 39
Table 64: SurVeil Drug Coated Balloon - Arterio Venous (AV) Fistulas - Product Status 39
Table 65: SurVeil Drug Coated Balloon - Arterio Venous (AV) Fistulas - Product Description 40
Table 66: SurVeil Drug Coated Balloon - Below The Knee (BTK) - Product Status 40
Table 67: SurVeil Drug Coated Balloon - Below The Knee (BTK) - Product Description 40
Table 68: SurVeil Drug Coated Balloon - SFA - Product Status 41
Table 69: SurVeil Drug Coated Balloon - SFA - Product Description 41
Table 70: SurModics, Inc. - Ongoing Clinical Trials Overview 42
Table 71: SurVeil Drug Coated Balloon - SFA - A Prospective, Multi-center, Single-arm Trial to Assess the Safety and Feasibility of the SurModics Drug Coated Balloon in the Treatment of Subjects with De Novo Lesions of the Femoropopliteal Artery 43
Table 72: Terumo Corporation Pipeline Products & Ongoing Clinical Trials Overview 44
Table 73: Drug Coated Balloon Catheter - Product Status 44
Table 74: Drug Coated Balloon Catheter - Product Description 45
Table 75: The Spectranetics Corporation Pipeline Products & Ongoing Clinical Trials Overview 46
Table 76: Stellarex Drug Coated Balloon - Below The Knee (BTK) - Product Status 46
Table 77: Stellarex Drug Coated Balloon - Below The Knee (BTK) - Product Description 47
Table 78: Stellarex Drug Coated Balloon - Superficial Femoral Artery - Product Status 47
Table 79: Stellarex Drug Coated Balloon - Superficial Femoral Artery - Product Description 48
Table 80: The Spectranetics Corporation - Ongoing Clinical Trials Overview 49
Table 81: Stellarex Drug Coated Balloon - Superficial Femoral Artery - ILLUMENATE First-in-Human (FIH) Study on the Safety and Effectiveness of Covidien’s Advanced Drug-coated Balloon (DCB) Technology 50
Table 82: Stellarex Drug Coated Balloon - Superficial Femoral Artery - Prospective, Single-arm, Global Multi-center Study to Evaluate Treatment of Obstructive Superficial Femoral Artery and/or Popliteal Lesions with a Novel Paclitaxel-coated Percutaneous Angioplasty Balloon (ILLUMENATE GLOBAL) 50
Table 83: Stellarex Drug Coated Balloon - Superficial Femoral Artery - Prospective, Single-arm, Multi-center, Pharmacokinetic Study to Evaluate Treatment of Obstructive Superficial Femoral Artery or Popliteal Lesions with a Novel Paclitaxel-coated Percutaneous Angioplasty Balloon 51
Table 84: Stellarex Drug Coated Balloon - Superficial Femoral Artery - Stellarex Vascular E-Registry 51
Table 85: Vascular Nanotransfer Technologies Pipeline Products & Ongoing Clinical Trials Overview 52
Table 86: Mitomycin-Based Drug Coated Balloon - Peripheral - Product Status 52
Table 87: Mitomycin-Based Drug Coated Balloon - Peripheral - Product Description 52
Table 88: Paclitaxel-Based Drug Coated Balloon - Peripheral - Product Status 53
Table 89: Paclitaxel-Based Drug Coated Balloon - Peripheral - Product Description 53
Table 90: Glossary 85

1.2 List of Figures
Figure 1: Peripheral Transluminal Angioplasty Peripheral Drug Eluting Balloons (DEB) - Pipeline Products by Stage of Development 9
Figure 2: Peripheral Transluminal Angioplasty Peripheral Drug Eluting Balloons (DEB) - Pipeline Products by Territory 10
Figure 3: Peripheral Transluminal Angioplasty Peripheral Drug Eluting Balloons (DEB) - Pipeline Products by Regulatory Path 11
Figure 4: Peripheral Transluminal Angioplasty Peripheral Drug Eluting Balloons (DEB) - Pipeline Products by Estimated Approval Date 12
Figure 5: Peripheral Transluminal Angioplasty Peripheral Drug Eluting Balloons (DEB) - Ongoing Clinical Trials 13

【掲載企業】

AnGes MG, Inc.
AngioCure, Inc.
AVIDAL Vascular GmbH
Bayer HealthCare AG
Contego Medical, LLC
Elixir Medical Corporation
eucatech AG
Lifetech Scientific (Shenzhen) Co., Ltd.
Medtronic plc
Micell Technologies, Inc.
Nipro Corporation
NuVascular Technologies Inc
QT Vascular Ltd.
QualiMed Innovative Medizinprodukte GmbH
Rontis AG
SiL Vascular Ltd
SurModics, Inc.
Terumo Corporation
The Spectranetics Corporation
Vascular Nanotransfer Technologies

【レポートのキーワード】

経皮的血管形成術(PTA)経皮的薬剤溶出性バルーン(DEB)

【免責事項】
※当レポート上の情報/データは調査会社が信頼できると判断した情報源から入手したものに基づき作成しましたが、その正確性・完全性を保証するものではありません。当レポートに記載された情報/データ/見解/仮説などは作成時点又は発行時点における調査会社の判断であり、その後の状況変化に応じて変更される場合があります。当レポート上の情報/データに基づいたお客様の意思決定又は実行による結果について、調査会社/発行会社/販売会社H&Iグローバルリサーチ(株)はその責を負いかねますのでご了承ください。英文資料の紹介ページにおける日本語題名/概要/目次はH&Iグローバルリサーチ(株)が翻訳した内容であり、翻訳の正確性・完全性を保証するものではありません。

★調査レポート[世界の経皮的血管形成術(PTA)経皮的薬剤溶出性バルーン(DEB)市場:医療機器パイプライン分析2016]についてメールでお問い合わせはこちら


※世界の市場調査資料 総合販売サイトMarketReport.jpはH&Iグローバルリサーチ株式会社が運営しております。海外進出、グローバル事業戦略策定、新規事業機会の発掘、競合他社の動向把握などに必要な情報やインサイトをお客様にご提供しております。H&Iグローバルリサーチ(登録第5864124号)及びH&I(登録第5783645号)はH&Iグローバルリサーチ株式会社の商標です。
※当サイトでは2016年12月03日現在 219,162 件の調査レポートを取り扱っております。当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。

◆H&Iグローバルリサーチのお客様(例)◆